November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Headed to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
First results of investigational epithelial separator reported
May 1st 2004Epi-K, an epithelial separator being developed by Moria, has been usedin a small Mexican study of 22 patients for the creation of epithelialflaps for the Epi-LASIK procedure, reported Barrie Soloway, MD, at the AmericanSociety of Cataract and Refractive Surgery (ASCRS) annual meeting.
Read More
FDA approval benefits presbyopic patients
May 1st 2004Irvine, CA-The FDA approval of the ViewPoint CK System (Refractec Inc.) for the NearVision conductive keratoplasty (CK) procedure marked a milestone as the first technology to improve near vision in presbyopic patients (See related story from Ophthalmology Times, March 1 issue). The laser-free procedure-which uses radiowaves to reshape the cornea-can be performed in less than 3 minutes with topical anesthesia in the ophthalmologist's office.
Read More
Results of a controlled Phase I/II study show that the bioerodable, sustained-release,dexamethasone implant (Posurdex, Allergan) results in a statistically significantincrease in ETDRS standardized visual acuity in eyes with persistent cystoidmacular edema (CME), said Mark S. Blumenkranz, MD.
Read More
Two Phase III studies are now underway evaluating ranibizumab (formerlyrhu Fab V2, Lucentis; Genentech) for the treatment of exudative age-relatedmacular degeneration (AMD). The studies are based on Phase I/II study results,demonstrating it is well tolerated and offers promising biological and clinicalactivity, said Jeffrey S. Heier, MD.
Read More
Real-world VISION trial demonstrates safety and efficacy of anti-VEGF in all AMD subtypes
April 26th 2004One-year data from the pivotal Phase II/III VEGF Inhibition Study inOcular Neovascularization (VISION) indicate that selective anti-VEGF165(Macugen, Eyetech/Pfizer) treatment improves visual outcomes and offersa highly favorable systemic and ocular safety profile, said Steven Schwartz,MD.
Read More
NIH director outlines new model for clinical research based on interdisciplinaryapproach
April 26th 2004Calling for an interdisciplinary approach to clinical research, StephenE. Strauss, MD, director of the National Center for Complementary and AlternativeMedicine at the National Institute of Health (NIH), outlined a comprehensiveplan for how research will some day be conducted in the United States. Theplan would incorporate the many fields of medicine with the many disciplinesin research to form a "common core of knowledge."
Read More
Anterior chamber angle-supported lens provides good UCVA
April 15th 2004Mannheim, Germany-The AcrySof phakic anterior chamber angle supported lens (Alcon) for the correction of high myopia provides patients with excellent uncorrected visual acuity (UCVA). Importantly, no progressive endothelial cell loss, angle deformation, or irritation developed, according to Michael C. Knorz, MD, who reported results from a phase I study of the lens.
Read More
ARVO 2004 Retina presentations
April 1st 2004Among the 233 sessions dedicated to retina, almost 75 are free papersand symposia sessions. The Editorial Advisory Board of OphthalmologyTimes reviewed the retina abstracts to be presented at this year's meeting.Some of the board's selections are highlighted here.
Read More
The program for Sunday, April 25, features a number of scientific offerings,but one highlight is the annual keynote address. It will be given duringa session scheduled from 5 to 7 p.m. in Ballroom A-D. This year's keynotespeaker is Stephen E. Straus, MD, director, National Center for Complementaryand Alternative Medicine, National Institutes for Health (NIH), Bethesda,MD. His address, entitled "Envisioning New Models for ClinicalResearch", will describe the NIH-developed "Roadmap"-astrategy for accelerating basic science discoveries and for translatingthat research into clinical practice.
Read More
Levofloxacin 1.5% earns FDA approval
April 1st 2004Minneapolis, MN-The new fluoroquinolone, levofloxacin 1.5% ophthalmic solution (IQUIX, Santen), has received FDA approval to be marketed for the treatment of bacterial corneal ulcer. The approval brings with it a milestone as the first current-generation fluoroquinolone with an indication for use in the management of that sight-threatening condition, explained Richard L. Lindstrom, MD.
Read More
Once-daily regimen may effectively lower IOP
April 1st 2004Sarasota, FL-Data from three clinical trials show that Travatan/Timolol Fixed Combination (TTFC), Alcon's investigational new drug to treat glaucoma, is a safe alternative to the two single compounds dosed concomitantly, the company says.
Read More
Investigational implant provides for aqueous outflow
March 15th 2004Anaheim, CA-Performing cataract surgery in an eye with a failing filtering bleb is a tricky business, which has been addressed by a few different procedures. Successful intervention can be achieved in carefully selected patients. However, in those in which intervention might be problematic, a new investigational device is under study to lower IOP, according to Reay H. Brown, MD.
Read More
Studies link tear film osmolarity, ocular surface disease
March 15th 2004New information regarding the adverse effects of tear film hyperosmolarity on the ocular surface lends further support to the efficacy of a hypotonic artificial tear product (TheraTears, Advanced Vision Research) in the management of dry eye.
Read More
Drug beneficial for those with or without Sj?gren's dry eye
March 15th 2004Anaheim, CA-Cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) provides similar, significant improvement in the signs and symptoms of dry eye in both patients with keratoconjunctivitis sicca (KCS) associated with autoimmune disease and in those with non-Sj?gren's KCS, said Scott M. Whitcup, MD, at the annual meeting of the American Academy of Ophthalmology.
Read More